Press coverage about Cleveland BioLabs (NASDAQ:CBLI) has trended positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cleveland BioLabs earned a media sentiment score of 0.30 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.7483759287555 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Cleveland BioLabs (NASDAQ CBLI) traded up 0.37% on Friday, reaching $2.73. The company had a trading volume of 30,433 shares. The company has a 50 day moving average price of $2.71 and a 200 day moving average price of $2.65. The stock’s market capitalization is $30.79 million. Cleveland BioLabs has a 52-week low of $1.22 and a 52-week high of $5.55.
Cleveland BioLabs (NASDAQ:CBLI) last posted its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.50) EPS for the quarter. Cleveland BioLabs had a negative net margin of 253.09% and a negative return on equity of 61.18%. The company had revenue of $0.21 million for the quarter. On average, equities research analysts anticipate that Cleveland BioLabs will post ($0.16) earnings per share for the current year.
Separately, ValuEngine cut Cleveland BioLabs from a “hold” rating to a “sell” rating in a report on Thursday, June 29th.
COPYRIGHT VIOLATION NOTICE: “Cleveland BioLabs (NASDAQ:CBLI) Earning Positive Press Coverage, Study Finds” was first reported by BNB Daily and is the property of of BNB Daily. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/positive-media-coverage-somewhat-unlikely-to-impact-cleveland-biolabs-nasdaqcbli-stock-price-updated.html.
About Cleveland BioLabs
Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.
Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.